Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.46 |
| ▸ | GCGR | P47871 | 3/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | CCNC | P24863 | 4/20 | 0.46 |
| ▸ | CDK8 | P49336 | 4/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.42 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377962 | 1.00 | HTR3A (0.47) | HTR3AMAPK14GCGRMAPK13MAPK12 | |
| SCHEMBL6371713 | 0.81 | MAPK14 (0.51) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL27627755 | 0.81 | MAPK14 (0.45) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL27627754 | 0.81 | MAPK14 (0.45) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL5769402 | 0.79 | CA12 (0.44) | — | |
| SCHEMBL31189709 | 0.78 | CCNC (0.68) | CCNCCDK8NEK1CYP46A1 | |
| SCHEMBL19064199 | 0.78 | SLC6A4 (0.51) | GCGRSLC6A4SLC6A3 | |
| SCHEMBL19083288 | 0.78 | SLC6A3 (0.44) | HTR3AMAPK14GCGRSLC6A4SLC6A3 | |
| SCHEMBL5732191 | 0.77 | PRKCZ (0.49) | MAPK14GCGR | |
| SCHEMBL31555567 | 0.77 | IMPDH2 (0.57) | MAPK14GCGRCCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4126878-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-115335057-A | Method for inhibiting casein kinase | 北京原基华毅生物科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115298183-A | Compounds as casein kinase inhibitors | 北京原基华毅生物科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20050043331-A1 | Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043331-A1 | Substituted 3-(2,5-disubstituted)pyridyl-4-aryl pyrroles for treating inflammatory diseases | TNF, TSLP, IRAK1 | HTR3A 2032/4885MAPK14 240/4885GCGR 2600/4885 |
| US-20230192699-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | CSNK2A3, CSNK1A1, CSNK1G3 | HTR3A 4494/4885MAPK14 76/4885GCGR 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.